Hikma Pharmaceuticals Secures Permanent J-Code for COMBOGESIC IV Injection
Elevating Access to Pain Management for Patients
London, UK – [Date]
Hikma Pharmaceuticals plc, a leading global provider of generic medicines, has announced the receipt of a permanent J-code from the Centers for Medicare & Medicaid Services (CMS) for COMBOGESIC IV acetaminophen and ibuprofen injection, a non-opioid pain reliever. This milestone significantly enhances access to this essential medication for patients in the United States.
COMBOGESIC IV is a fixed-dose combination of acetaminophen and ibuprofen, providing a safe and effective option for the management of moderate to severe pain. The permanent J-code assignment streamlines reimbursement processes, ensuring timely access to this vital pain management therapy for patients in various healthcare settings.
Hikma Pharmaceuticals has a long-standing commitment to expanding patient access to affordable and high-quality medicines. With over 40 years of experience, the company has a proven track record of delivering innovative generic products that meet the evolving needs of patients and healthcare providers.
The permanent J-code for COMBOGESIC IV is a testament to Hikma Pharmaceuticals' unwavering dedication to improving patient outcomes. By facilitating seamless reimbursement, the company is further empowering healthcare providers to optimize pain management strategies and deliver exceptional care to their patients.
Comments